NLRP3 and edema: Interfering with PTPN22 can reduce the expression of IL-1β and IL-18 by inhibiting the activation of the NLRP3 inflammasome to reduce inflammatory responses, thereby improving neurological dysfunction and reducing cerebral edema in ICH rats [23].